Skip to main content
IOVA
NASDAQ Life Sciences

Iovance Updates Corporate Presentation with Record Q2 Revenue, Margin Gains, and Pipeline Progress

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$6.19
Mkt Cap
$2.773B
52W Low
$1.76
52W High
$6.39
52W Position info
252% above low
Off High info
3.1% below high
Rel. Volume info
4.6× avg
Market data snapshot near publication time

IOVA has more than doubled off its 52-week low of $1.76 on elevated volume (4.6× avg).

Summary

Iovance's August 2026 corporate presentation highlights record Q2 revenue of ~$99M, a 56% gross margin, and a cash runway into 2H 2028, alongside pipeline updates including the SARATOGA trial start and NSCLC launch timeline.


Key Events · Earnings and Guidance · IOVA

  • Record Q2 Revenue and Margin

    Q2 2026 revenue reached ~$99M, exceeding guidance by >10% and growing 66% YoY, with gross margin from cost of sales improving to 56%.

  • Extended Cash Runway

    Cash position of ~$304M as of June 30, 2026, supports operations into the second half of 2028, reducing near-term financing risk.

  • Commercial Expansion Metrics

    Over 95 authorized treatment centers are now active, and ~2,000 patients have been treated with commercial and clinical TIL products, demonstrating broad market access.

  • Pipeline Progress and Upcoming Milestones

    The SARATOGA registrational trial in soft tissue sarcomas commenced in Q2 2026, and a potential NSCLC launch is targeted for 2H 2027, leveraging existing infrastructure.


Analysis · IOVA · Life Sciences

Iovance's updated corporate presentation reinforces the strong Q2 2026 results reported earlier today, highlighting record revenue of ~$99M (up 66% YoY and >10% above guidance), a 56% gross margin from cost of sales, and a cash runway extended into the second half of 2028. The presentation also details pipeline advancements, including the commencement of the SARATOGA registrational trial in soft tissue sarcomas and progress toward a potential NSCLC launch in 2H 2027. While the financial figures were already disclosed in the 10-Q and 8-K filed earlier today, the presentation provides additional operational metrics—such as >95 authorized treatment centers and ~2,000 patients treated—that underscore the commercial traction and scalability of the TIL platform. The stock is trading near its 52-week high, reflecting market optimism around the growth trajectory.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, IOVA was trading at $6.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $1.76 to $6.39. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

IOVA - Latest Insights

IOVA
Nov 05, 2026, 9:15 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $8.43
Real-time Price: $7.40 info
Change: -$1.04 (-12%) info
Market Cap: $3.401B info
IOVA
Nov 05, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $9.24
Real-time Price: $7.40 info
Change: -$1.85 (-20%) info
Market Cap: $3.401B info
IOVA
Oct 29, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $9.38
Real-time Price: $7.40 info
Change: -$1.98 (-21%) info
Market Cap: $3.401B info
IOVA
Oct 29, 2026, 3:11 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $9.69
Real-time Price: $7.40 info
Change: -$2.29 (-24%) info
Market Cap: $3.401B info
IOVA
Oct 29, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $13.13
Real-time Price: $7.40 info
Change: -$5.74 (-44%) info
Market Cap: $3.401B info